Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Hosted on MSN14h
Amgen price target lowered to $295 from $310 at CitiCiti lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...
The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...
US Dollar South African Rand, Coca-Cola Co, Eli Lilly and Company, Apple Inc. Read Vestact 's latest article on Investing.com South Africa.
The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria and tuberculosis, as well as ...
Blue Tower Asset Management's Global Value strategy returned 4.95% in Q4 (5.23% gross) and 22.27% net for 2024 (23.53% gross) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback